Scribe Therapeutics上調規模1.287億美元IPO後將在紐約上市

路透中文

昨天

BUZZ-Scribe <a href="https://laohu8.com/S/LENZ">Therapeutics</a>上調規模1.287億美元IPO後將在紐約上市

7月24日 - ** 基因編輯初創公司 Scribe Therapeutics（SCTX.O）在將美國首次公開募股（IPO）規模擴大至 1.287 億美元后，將於周五晚些時候在紐約證券交易所上市

** 總部位於加利福尼亞州阿拉米達的SCTX以每股15美元的價格售出約860萬股 (link)。

** SCTX正在構建針對心代謝疾病的基因藥物產品組合，此前曾計劃以每股13至15美元的價格發行720萬股

** 其主要候選藥物STX-1150正在研發中，旨在降低低密度脂蛋白膽固醇水平，這是心血管風險的關鍵驅動因素

** 據美國心臟協會統計，美國每40秒就有人發生心臟病發作，每年心臟病給該國造成的經濟負擔超過4000億美元

** 利林克合夥公司（Leerink Partners）、高盛（Goldman Sachs）、古根海姆證券（Guggenheim Securities）和富國證券（Wells Fargo Securities）擔任本次發行的聯合簿記管理人

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2653139084"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653139084\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653139084?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-24 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653139084","market":"us","top_or_hot":-1,"title":"Scribe Therapeutics上調規模1.287億美元IPO後將在紐約上市","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Scribe <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>上調規模1.287億美元IPO後將在紐約上市</title></head><body><p><span>7月24日</span><span> - </span>** 基因編輯初創公司 Scribe Therapeutics（<span>SCTX.O</span>）在將美國首次公開募股（IPO）規模擴大至 1.287 億美元后，將於周五晚些時候在紐約證券交易所上市</p><p>** 總部位於加利福尼亞州阿拉米達的SCTX以每股15美元的價格售出約860萬股 (link)。</p><p>** SCTX正在構建針對心代謝疾病的基因藥物產品組合，此前曾計劃以每股13至15美元的價格發行720萬股</p><p>** 其主要候選藥物STX-1150正在研發中，旨在降低低密度脂蛋白膽固醇水平，這是心血管風險的關鍵驅動因素</p><p>** 據美國心臟協會統計，美國每40秒就有人發生心臟病發作，每年心臟病給該國造成的經濟負擔超過4000億美元</p><p>** 利林克合夥公司（Leerink Partners）、<a href=\"https://laohu8.com/S/GS\">高盛</a>（Goldman Sachs）、古根海姆證券（Guggenheim Securities）和富國證券（<a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> Securities）擔任本次發行的聯合簿記管理人</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scribe Therapeutics上調規模1.287億美元IPO後將在紐約上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScribe Therapeutics上調規模1.287億美元IPO後將在紐約上市\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-07-24 20:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Scribe <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>上調規模1.287億美元IPO後將在紐約上市</title></head><body><p><span>7月24日</span><span> - </span>** 基因編輯初創公司 Scribe Therapeutics（<span>SCTX.O</span>）在將美國首次公開募股（IPO）規模擴大至 1.287 億美元后，將於周五晚些時候在紐約證券交易所上市</p><p>** 總部位於加利福尼亞州阿拉米達的SCTX以每股15美元的價格售出約860萬股 (link)。</p><p>** SCTX正在構建針對心代謝疾病的基因藥物產品組合，此前曾計劃以每股13至15美元的價格發行720萬股</p><p>** 其主要候選藥物STX-1150正在研發中，旨在降低低密度脂蛋白膽固醇水平，這是心血管風險的關鍵驅動因素</p><p>** 據美國心臟協會統計，美國每40秒就有人發生心臟病發作，每年心臟病給該國造成的經濟負擔超過4000億美元</p><p>** 利林克合夥公司（Leerink Partners）、<a href=\"https://laohu8.com/S/GS\">高盛</a>（Goldman Sachs）、古根海姆證券（Guggenheim Securities）和富國證券（<a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> Securities）擔任本次發行的聯合簿記管理人</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2750360641.GBP","symbol_name":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4S43Q10T:1","article_id":"2653139084","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653139084","pubTimestamp":1784894948,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Scribe Therapeutics上調規模1.287億美元IPO後將在紐約上市7月24日-** 基因編輯初創公司 Scribe Therapeutics在將美國首次公開募股規模擴大至 1.287 億美元后，將於周五晚些時候在紐約證券交易所上市** 總部位於加利福尼亞州阿拉米達的SCTX以每股15美元的價格售出約860萬股 。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","BK4127":"投资银行业与经纪业","SCTX":"Scribe Therapeutics, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","MNSH":"MNSN HLDGS INC.","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","BK4516":"特朗普概念","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","BK4504":"桥水持仓","GSX":"Tradr 2X Long GS Daily ETF","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","BK4588":"碎股","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BK4550":"红杉资本持仓","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4552":"Archegos爆仓风波概念","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","BK4585":"ETF&股票定投概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"Scribe Therapeutics raises size by $128.7 million to list in New York after IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNSH":0.9,"SCTX":0.9,"GSX":0.6},"content_text":"BUZZ-Scribe Therapeutics上調規模1.287億美元IPO後將在紐約上市7月24日 - ** 基因編輯初創公司 Scribe Therapeutics（SCTX.O）在將美國首次公開募股（IPO）規模擴大至 1.287 億美元后，將於周五晚些時候在紐約證券交易所上市** 總部位於加利福尼亞州阿拉米達的SCTX以每股15美元的價格售出約860萬股 (link)。** SCTX正在構建針對心代謝疾病的基因藥物產品組合，此前曾計劃以每股13至15美元的價格發行720萬股** 其主要候選藥物STX-1150正在研發中，旨在降低低密度脂蛋白膽固醇水平，這是心血管風險的關鍵驅動因素** 據美國心臟協會統計，美國每40秒就有人發生心臟病發作，每年心臟病給該國造成的經濟負擔超過4000億美元** 利林克合夥公司（Leerink Partners）、高盛（Goldman Sachs）、古根海姆證券（Guggenheim Securities）和富國證券（Wells Fargo Securities）擔任本次發行的聯合簿記管理人","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}